Chattem's CHTT second-quarter results were in line with our expectations, so our fair value estimate for the shares remains unchanged. The firm is already reaping the benefits of the five brands it acquired from Johnson & Johnson JNJ in early January in the form of sales growth and improving ...
Research and Markets: Global Glycine Industry Report 2015
These great businesses are undervalued and run by CEOs that are looking out for the best interests of shareholders.
We believe breakups could unlock value for big pharma shareholders.